Latest Conference Articles

Opdivo Combined with Yervoy or Chemo Improves Survival in Unresectable and Advanced Esophageal Cancer

Opdivo Combined with Yervoy or Chemo Improves Survival in Unresectable and Advanced Esophageal Cancer

June 5th 2021, 3:00pm

ASCO Annual Meeting

Adding Opdivo to treatment with Yervoy or chemotherapy improved survival, compared with chemotherapy alone in patients with unresectable and advanced esophageal cancer.

Novel Drug-Chemo Combo Significantly Improves Survival in Rare Form of Head and Neck Cancer

Novel Drug-Chemo Combo Significantly Improves Survival in Rare Form of Head and Neck Cancer

June 5th 2021, 1:00pm

ASCO Annual Meeting

The addition of a novel drug to the chemotherapies gemcitabine and cisplatin significantly improved a survival outcome in patients with a rare form of head and neck cancer, compared with chemotherapy alone.

Extraordinary Healer® Award for Oncology Nursing 2021

Extraordinary Healer® Award for Oncology Nursing 2021

April 30th 2021, 3:22pm

Extraordinary Healer® Award for Oncology Nursing

View the entire 2021 Extraordinary Healer® Award for Oncology Nursing virtual presentation here!

Emerging Therapies Show Promise in Treating Metastatic Breast Cancer

Emerging Therapies Show Promise in Treating Metastatic Breast Cancer

March 16th 2021, 1:00pm

Educated Patient® Breast Cancer Summit

An expert discusses the potential that several novel therapies hold in treating metastatic breast cancer, including PARP inhibitors, immunotherapy and antibody drug conjugates. Each therapy type has an FDA-approved option to potentially provide patients with better outcomes and quality of life.

The Future of Adoptive Cellular Therapy in Lung Cancer

The Future of Adoptive Cellular Therapy in Lung Cancer

March 15th 2021, 1:00pm

Educated Patient® Lung Cancer Summit

In the field of lung cancer, a number of current studies evaluating the efficacy of adoptive cellular therapies may one day offer patients with non-small cell lung cancer a “high risk, high reward” treatment option, according to Dr. Ben Creelan of the Moffitt Cancer Center.

Educated Patient® Multiple Myeloma Summit: March 13, 2021

Educated Patient® Multiple Myeloma Summit: March 13, 2021

March 13th 2021, 3:00pm

2021 Educated Patient Summits

View the full CURE Educated Patient Multiple Myeloma Summit on demand.

Geriatric Assessment and More Inclusive Clinical Trials Needed for Older Adults with Lung Cancer

Geriatric Assessment and More Inclusive Clinical Trials Needed for Older Adults with Lung Cancer

March 12th 2021, 10:00pm

Educated Patient® Lung Cancer Summit

As the population ages, the incidence of older adults being diagnosed with lung cancer is increasing, though data on how to specifically treat this population are lacking.

How Targeted Therapies Are Changing the Breast Cancer Treatment Landscape

How Targeted Therapies Are Changing the Breast Cancer Treatment Landscape

March 11th 2021, 2:00pm

Educated Patient® Breast Cancer Summit

Targeted therapies that attack cancer in a more precise way than traditional chemotherapy are being used more often in the field of breast cancer, but the solution in utilizing them lies within the patient-oncologist relationship, according to an expert from the Massachusetts General Hospital Cancer Center.

Looking at the Big Picture of Small Cell Lung Cancer

Looking at the Big Picture of Small Cell Lung Cancer

March 10th 2021, 7:00pm

Educated Patient® Lung Cancer Summit

An expert discusses ways that small cell lung cancer is diagnosed, how to treat it and how to pivot if the disease spreads or recurs. He also focuses on efforts in the clinical trial space to potentially treat patients more effectively.

How Patients With Cancer Can Boost Their ‘Mindfulness Muscle’ and Improve Resiliency

How Patients With Cancer Can Boost Their ‘Mindfulness Muscle’ and Improve Resiliency

March 10th 2021, 2:00pm

Educated Patient® Breast Cancer Summit

Mindfulness practices have been associated with improved mental health outcomes in patients with cancer. Here, an expert shares tips on how patients can strengthen their “mindfulness muscle.”

‘Lost in Transition’ After Breast Cancer

‘Lost in Transition’ After Breast Cancer

March 9th 2021, 4:00pm

Educated Patient® Breast Cancer Summit

With more than 4 million breast cancer survivors in the U.S., survivorship care and understanding what happens to patients after surviving is of the utmost importance. An expert explains some side effects survivors may experience and treatments to help.

Educated Patient® Breast Cancer Summit: March 7, 2021

Educated Patient® Breast Cancer Summit: March 7, 2021

March 7th 2021, 3:00pm

2021 Educated Patient Summits

View the full CURE Educated Patient Breast Cancer Summit on demand.

Educated Patient® Lung Cancer Summit: March 6, 2021

Educated Patient® Lung Cancer Summit: March 6, 2021

March 6th 2021, 3:00pm

2021 Educated Patient Summits

View the full CURE Educated Patient Lung Cancer Summit on demand.

How One Organization is Helping People Navigate the ‘Pain, Confusion and Chaos’ of a Cancer Diagnosis

How One Organization is Helping People Navigate the ‘Pain, Confusion and Chaos’ of a Cancer Diagnosis

February 23rd 2021, 10:00pm

DONNA Foundation Marathon Weekend

A cancer diagnosis often comes with concerns of what’s next for patients. One concern is how they’re going to afford their treatments. Here, a panel of experts discuss what options are available.

Shattering Myths: How Patients With Cancer Can Become Better Health Advocates

Shattering Myths: How Patients With Cancer Can Become Better Health Advocates

February 23rd 2021, 7:00pm

DONNA Foundation Marathon Weekend

There are two myths that patients with cancer believe when it comes to being health advocates. Here, a panel of experts look to dispel those myths to help patients become better advocates.

Immunotherapy Combinations Offer ‘Hope and Promise’ for Patients with Advanced Renal Cell Carcinoma

Immunotherapy Combinations Offer ‘Hope and Promise’ for Patients with Advanced Renal Cell Carcinoma

February 23rd 2021, 2:00pm

ASCO Genitourinary Symposium

Positive results from the phase 3 CLEAR clinical trial, presented at the 2021 ASCO Genitourinary Cancers Symposium, are just one more dataset that could offer “a sense of hope and promise” for patients with advanced renal cell carcinoma (RCC), says the study’s lead author, Dr. Robert J. Motzer.

‘Knowledge is Power’: Advocating for More Representation in Cancer-Related Clinical Trials

‘Knowledge is Power’: Advocating for More Representation in Cancer-Related Clinical Trials

February 19th 2021, 10:00pm

DONNA Foundation Marathon Weekend

There are several health equity barriers in patients with cancer, one of which involves adequate access to clinical trials. Here, a panel of experts and a cancer survivor discuss ways to improve access.

Cabometyx Significantly Prolongs Survival Over Sutent in Rare Form of Kidney Cancer

Cabometyx Significantly Prolongs Survival Over Sutent in Rare Form of Kidney Cancer

February 18th 2021, 2:00pm

ASCO Genitourinary Symposium

The study results, according to one expert, show that Cabometyx should be considered the new standard for systemic therapy in patients with metastatic papillary renal cell carcinoma.

Padcev Continues to Show Promise in Patients with Previously Treated Bladder Cancer

Padcev Continues to Show Promise in Patients with Previously Treated Bladder Cancer

February 15th 2021, 10:00pm

ASCO Genitourinary Symposium

Treatment with Padcev, compared to chemotherapy, continues to show better results in patients with advanced urothelial carcinoma who had previously received certain therapies.

Lenvima Plus Keytruda Associated With Better Results Than Sutent Alone in Patients With Advanced Type of Kidney Cancer

Lenvima Plus Keytruda Associated With Better Results Than Sutent Alone in Patients With Advanced Type of Kidney Cancer

February 13th 2021, 10:00pm

ASCO Genitourinary Symposium

The results of the phase 3 trial, according to one expert, support the use of Lenvima with Keytruda as a possible first-line treatment option for patients with advanced renal cell carcinoma.

Novel Therapy Demonstrates Limited Activity and Poor Safety Outcomes in Patients With Metastatic Renal Cell Carcinoma

Novel Therapy Demonstrates Limited Activity and Poor Safety Outcomes in Patients With Metastatic Renal Cell Carcinoma

February 13th 2021, 6:00pm

ASCO Genitourinary Symposium

Treatment with sapanisertib was associated with limited activity and poor safety outcomes in patients with refractory metastatic renal cell carcinoma.

Communication And Support Can Help Patients With Cancer Improve Their Quality of Life During Treatment

Communication And Support Can Help Patients With Cancer Improve Their Quality of Life During Treatment

February 13th 2021, 4:00pm

ASCO Genitourinary Symposium

For patients to maintain or improve their quality of life through their cancer treatment, it is pivotal that they communicate with their health care team.

New Options for Renal Cell Carcinoma Could Offer Hope, But Sequencing and a Personalized Approach Are Critical

New Options for Renal Cell Carcinoma Could Offer Hope, But Sequencing and a Personalized Approach Are Critical

February 12th 2021, 10:20pm

ASCO Genitourinary Symposium

Clinical trials remain the gold standard when it comes to finding new treatment options for patients, particularly when it comes to renal cell carcinoma. But even if the results are positive and this combination proves to be beneficial, patients should still discuss all of their options with their oncologist to find the right sequence of treatment, says one expert.

Zytiga and Prednisone Plus Erleada Reduces Risk of Disease Progression in Prostate Cancer Subtype

Zytiga and Prednisone Plus Erleada Reduces Risk of Disease Progression in Prostate Cancer Subtype

February 12th 2021, 8:45pm

ASCO Genitourinary Symposium

The combination of Erleada, Zytiga and the steroid prednisone was associated with a trend toward better survival outcomes in certain patients with chemotherapy-naive metastatic castration-resistant prostate cancer.

Opdivo-Cabometyx Combo Improves Quality of Life in Kidney Cancer Subtype

Opdivo-Cabometyx Combo Improves Quality of Life in Kidney Cancer Subtype

February 12th 2021, 6:30pm

ASCO Genitourinary Symposium

Front-line treatment with Opdivo plus Cabometyx improved health-related quality of life outcomes in patients with advanced renal cell carcinoma.

Front-Line Immunotherapy Improves Survival in Kidney Cancer Subtype, Versus Certain Targeted Therapies

Front-Line Immunotherapy Improves Survival in Kidney Cancer Subtype, Versus Certain Targeted Therapies

February 11th 2021, 9:56pm

ASCO Genitourinary Symposium

Patients with metastatic non–clear cell renal cell carcinoma who receive immune checkpoint inhibitor–based regimens as a first treatment option may have improved survival, versus those who receive select targeted therapies.

Starting Treatment With Lenvima at a Higher Dose Improves Quality of Life and Symptom Control in Type of Kidney Cancer

Starting Treatment With Lenvima at a Higher Dose Improves Quality of Life and Symptom Control in Type of Kidney Cancer

February 11th 2021, 8:49pm

ASCO Genitourinary Symposium

A higher starting dose of Lenvima, compared with a lower starting dose, prolonged the time that patients with renal cell carcinoma experienced negative effects on factors including social and physical functioning, financial difficulties and cogitative functioning over time.

New Combination Could Prove Beneficial After Immunotherapy in Patients with Clear Cell RCC

New Combination Could Prove Beneficial After Immunotherapy in Patients with Clear Cell RCC

February 11th 2021, 6:59pm

ASCO Genitourinary Symposium

The combination of Lenvima plus everolimus was found to be an acceptable treatment option for patients who have previously received immunotherapy for clear cell renal cell carcinoma, according to the findings of an exploratory analysis of a phase 2 trial presented virtually at the 2021 ASCO Genitourinary Cancers Symposium.

Educated Patient Women's Cancers Summit: December 19, 2020

Educated Patient Women's Cancers Summit: December 19, 2020

December 19th 2020, 3:00pm

2020 Educated Patient Summits

View the full CURE Educated Patient Women's Cancer Summit on demand.

Educated Patient Lung Cancer Summit On-Demand: Dec. 12, 2020

Educated Patient Lung Cancer Summit On-Demand: Dec. 12, 2020

December 16th 2020, 7:00pm

2020 Educated Patient Summits

View all three sessions of the CURE Educated Patient Lung Cancer Summit here!